The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for lenacapavir (Gilead Sciences Pty Ltd)
Active ingredients
lenacapavir
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
[TRADENAME], in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatrics weighing at least 35 kg with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
Therapeutic area
Infectious diseases